Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer

被引：0
|
作者：
O B Goodman
T W Flaig
A Molina
P F A Mulders
K Fizazi
H Suttmann
J Li
T Kheoh
J S de Bono
H I Scher
机构：
[1] Comprehensive Cancer Centers of Nevada,Department of Medical Oncology
[2] University of Colorado Cancer Center,undefined
[3] Janssen Research & Development,undefined
[4] Radboud University Medical Centre,undefined
[5] Institut Gustave Roussy,undefined
[6] University of Paris Sud,undefined
[7] Urologikum Hamburg,undefined
[8] Janssen Research & Development,undefined
[9] The Institute of Cancer Research and The Royal Marsden Hospital,undefined
[10] Memorial Sloan-Kettering Cancer Center and Weill-Cornell Medical College,undefined
来源：
Prostate Cancer and Prostatic Diseases | 2014年 / 17卷
关键词：
abiraterone acetate; liver metastases; metastatic prostate cancer; survival; visceral disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：34 / 39
页数：5
相关论文
共 50 条
  • [21] Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results
    Chi, Kim N.
    Fleshner, Neil
    Chiuri, Vincenzo Emanuele
    Van Bruwaene, Siska
    Hafron, Jason
    McNeel, Douglas G.
    De Porre, Peter
    Maul, Raymond Scott
    Daksh, Mahesh
    Zhong, Xiaogang
    Mason, Gary E.
    Tutrone, Ronald F.
    ONCOLOGIST, 2023, 28 (05): : E309 - E312
  • [22] Abiraterone in the treatment of metastatic castration-resistant prostate cancer
    Mostaghel, Elahe A.
    CANCER MANAGEMENT AND RESEARCH, 2014, 6 : 39 - 51
  • [23] Abiraterone AcetateIn Metastatic Castration-Resistant Prostate Cancer
    Lily P. H. Yang
    Drugs, 2011, 71 : 2067 - 2077
  • [24] Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer
    Ferrero, Jean-Marc
    Mahammedi, Hakim
    Gravis, Gwenaelle
    Roubaud, Guilhem
    Beuzeboc, Philippe
    Largillier, Remi
    Borchiellini, Delphine
    Linassier, Claude
    Ebran, Nathalie
    Pace-Loscos, Tanguy
    Etienne-Grimaldi, Marie-Christine
    Schiappa, Renaud
    Gal, Jocelyn
    Milano, Gerard
    PHARMACEUTICS, 2023, 15 (02)
  • [25] A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer
    McKay, Rana R.
    Werner, Lillian
    Jacobus, Susanna J.
    Jones, Xandra
    Mostaghel, Elahe A.
    Marck, Brett T.
    Choudhury, Atish D.
    Pomerantz, Mark M.
    Sweeney, Christopher J.
    Slovin, Susan F.
    Morris, Michael J.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    CANCER, 2019, 125 (04) : 524 - 532
  • [26] Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer
    Scott, Lesley J.
    DRUGS, 2017, 77 (14) : 1565 - 1576
  • [27] Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials
    Fizazi, K.
    Flaig, T. W.
    Stoeckle, M.
    Scher, H. I.
    de Bono, J. S.
    Rathkopf, D. E.
    Ryan, C. J.
    Kheoh, T.
    Li, J.
    Todd, M. B.
    Griffin, T. W.
    Molina, A.
    Ohlmann, C. H.
    ANNALS OF ONCOLOGY, 2016, 27 (04) : 699 - 705
  • [28] Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients
    Efstathiou, Eleni
    Titus, Mark
    Wen, Sijin
    Troncoso, Patricia
    Hoang, Anh
    Corn, Paul
    Prokhorova, Ina
    Araujo, John
    Dmuchowski, Carl
    Melhem-Bertrandt, Amal
    Patil, Shiva
    Logothetis, Christopher J.
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (01): : 119 - 127
  • [29] Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer
    Lesley J. Scott
    Drugs, 2017, 77 : 1565 - 1576
  • [30] Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer
    Zhang, Tian
    Zhu, Jason
    George, Daniel J.
    Armstrong, Andrew J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (04) : 473 - 485
12345